Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma

References

• Committee for Medicinal Products for Human Use (European Union). Assessment report for Tepadina. Document reference EMA/CHMP/55233/2010. Procedure number EMEA/H/C/001046. London, UK: European Medicines Agency; 2010. Available from: http://www.ema.europa.eu/ema/
   Google Scholar
• Heideman RL, Cole DE, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989;49:736–741.
   PubMed Web of Science ®Google Scholar
• Heideman RL, Packer RJ, Reaman GH, et al. A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer 1993;72:271–275.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. In: Pharmaceuticals, Vol. 100A, A review of human carcinogens. Lyon, France: WHO; 2012. Available from: http://www.iarc.fr/
   Google Scholar
• Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus 2006;21:E12.
   Google Scholar
• Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 2009;36(Suppl. 2):S2–S16.
   PubMed Web of Science ®Google Scholar
• Table 3. Orphan-designated products with marketing approvals. Silver Spring, MD: US Food and Drug Administration. 14 August 2013. Available from: www.accessdata.fda.gov/scripts/opdlisting/oopd/
   Google Scholar
• Alberta Provincial Hematology TumourTeam synthesis. Lymphoma. Clinical practice guideline LYHE-002. 2011. Available from: www.albertahealthservices.ca/hp/if-hp-cancer-guide-lyhe002-lymphoma.pdf
   Google Scholar
• Soussain C, Merle-Beral H, Reux I, et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma 1996;23: 339–345.
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742–749.
   PubMed Web of Science ®Google Scholar
• Cheng T, Forsyth P, Chaudhry A, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003;31:679–685.
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Levy V. [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. Bull Cancer 2004;91:189–192.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865–3870.
   PubMed Web of Science ®Google Scholar
• Montemurro M, Kiefer T, Schuler F, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007;18:665–671.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Muller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93:147–148.
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008;26:2512–2518.
   PubMed Web of Science ®Google Scholar
• Sierra del Rio M, Choquet S, Hoang-Xuan K, et al. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. J Neurooncol 2011;105:409–414.
   PubMed Web of Science ®Google Scholar
• Alimohamed N, Daly A, Owen C, et al. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leuk Lymphoma 2012;53:862–867.
   PubMed Web of Science ®Google Scholar
• Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012;18:76–83.
   PubMed Web of Science ®Google Scholar
• Kiefer T, Hirt C, Späth C, et al. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. Ann Oncol 2012;23:1809–1812.
   PubMed Web of Science ®Google Scholar
• Soussain C, Choquet S, Fourme E, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 2012;97:1751–1756.
   PubMed Web of Science ®Google Scholar
• Sica S, Cicconi S, Sora F, et al. Inappropriate antidiuretic hormone secretion after high-dose thiotepa. Bone Marrow Transplant 1999;24:571–572.
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF. Favorable outcome of primary CNS anaplastic large cell lymphoma in an immunocompetent patient. J Pediatr Hematol Oncol 2009;31:128–130.
   PubMed Web of Science ®Google Scholar
• Shah AC, Kelly DR, Nabors LB, et al. Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients. Pediatr Blood Cancer 2010;55:1227–1230.
   PubMed Web of Science ®Google Scholar
• Fischer L, Koch A, Schlegel U, et al. Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions. J Neurooncol 2011;102:163–166.
   PubMed Web of Science ®Google Scholar
• Geet Yi, Lai G, Koo YX, et al. Use of rituximab in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma in a mycophenolate mofetil treated patient with lupus nephritis. Acta Oncol 2011;50:144–145.
   PubMed Web of Science ®Google Scholar
• Kasenda B, Schorb E, Fritsch K, et al. Primary CNS lymphoma-radiation-free salvage therapy by second autologous stem cell transplantation. Biol Blood Marrow Transplant 2011;17:281–283.
   PubMed Web of Science ®Google Scholar
• Miura Y, Toyooka N, Iwai F, et al. [Sustained complete remission of intravascular large B-cell lymphoma with recurrent CNS involvement by autologous peripheral blood stem cell transplantation preconditioned with TBC regimen]. Rinsho ketsueki 2011;52:1876–1881.
   PubMedGoogle Scholar